All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants MRG-106 Orphan Drug Designation for Mycosis Fungoides type Cutaneous T-Cell Lymphoma
On 31st March 2017, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation status to MRG-106 for the treatment of Mycosis Fungoides type Cutaneous T-Cell Lymphoma (MF-CTCL).
MicroRNA-155 has been reported at aberrantly high levels in a range of hematological malignancies and has various roles in differentiation and proliferation of blood cells and lymphocytes. miRagen Therapeutics’ MRG-106 is a microRNA-155 inhibitor.
Currently, the safety, tolerability, and pharmacokinetics of intravenous MRG-106 is being evaluated in a phase I clinical trial (NCT02580552) of patients with MF-CTCL. The estimated primary completion date is July 2017.
References
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?